The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available evidence and combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/mL or greater or a historical blood eosinophil threshold of 300 cells/mL or greater will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment. (J Allergy Clin Immunol 2017;140:1509-18.)
Key words: Eosinophils, biomarkers, severe eosinophilic asthma Biological therapies, in addition to regular controller medication, for patients with severe asthma are becoming the new standard of care for patients who were previously without alternative treatment options. 1 Omalizumab, which neutralizes IgE, was the first biologic introduced for asthma in 2003
for patients who could not achieve asthma control with inhaled corticosteroids (ICSs), leukotriene inhibitors, and bronchodilators. [1] [2] [3] [4] However, targeting treatment based on total or allergen-specific IgE levels was not completely effective in selecting patients likely to respond to therapy. 5, 6 More recently, biologic therapies that disrupt IL-5 signaling and ultimately reduce eosinophil counts in blood and lung tissue (mepolizumab [GlaxoSmithKline, Research Triangle Park, NC] and reslizumab [Teva, Petach Tikva , Israel]) [7] [8] [9] [10] have been approved for treatment in patients with severe asthma and an eosinophilic phenotype (with baseline eosinophil counts at different threshold levels), a condition now termed severe eosinophilic asthma. [11] [12] [13] In addition, benralizumab (AstraZeneca, Cambridge, United Kingdom), which is currently in development, depletes eosinophil counts by antibody-dependent cell-mediated cytotoxicity through binding to the a chain of the IL-5 receptor on the eosinophil surface. [14] [15] [16] In clinical trials all 3 anti-targeted IL-5 pathway therapies (mepolizumab, reslizumab, and benralizumab) reduced rates of exacerbations in patients with severe eosinophilic asthma. 8, 14, 15, [17] [18] [19] In addition, mepolizumab and benralizumab have been shown to reduce or eliminate the dependency for oral corticosteroids (OCSs) without a loss of asthma control. 20, 21 Some overlap in the asthma phenotypes, principally severe allergic asthma and severe eosinophilic asthma, can lead to an overlap in eligibility for the different biological therapies. 22 In circumstances in which the patient can be identified clearly as having a particular phenotype, the treatment options recommended in the Global Strategy for Asthma Management and Prevention (Global Initiative for Asthma [GINA] ) guidelines are to prescribe anti-IgE and anti-IL-5 therapies, respectively. 1 Integral to the successful clinical development of these drugs has been identification and use of biomarkers to identify patients likely to respond to treatment.
A biomarker is any characteristic that can be objectively measured and evaluated as an indicator of normal biological processes, pathologic processes, or responses associated with a therapeutic intervention. 23 There are several different types Pharmacodynamic biomarkers inform on the biological response to pharmacologic intervention. For example, the effect of anticoagulation treatments (eg, warfarin) for thromboembolic disease can be assessed by measuring prothrombin time as a pharmacodynamic biomarker. 24 A predictive biomarker identifies patients likely to derive benefit from treatment or identify patients who are unlikely to respond, which thus influences clinical decisions. Although there are no predictive biomarkers for heart failure currently in routine use, 25 predictive biomarkers are used routinely in oncology. For example, for patients with invasive breast cancer, overexpression or gene amplification of human epidermal growth factor receptor 2 is predictive of response to drugs targeted at the human epidermal growth factor receptor 2, such as trastuzumab, pertuzumab, and lapatinib. 26 Conversely, in patients with rheumatoid arthritis, a characteristic interferon type I genetic signature was found to be predictive of nonresponse to rituximab. 27 A diagnostic biomarker identifies patients with a specific condition or disease, whereas a prognostic biomarker categories the risk of disease progression in the absence of treatment. In the case of heart failure, the presence of increased concentrations of B-type natriuretic peptide, which is produced in response to myocardial stress, has both positive and negative diagnostic value. 28 B-type natriuretic peptide concentration on admission to the hospital also has a linear relationship with morbidity and mortality outcomes and is the gold standard prognostic biomarker for heart failure. 28 In the case of asthma, early observations on the association between eosinophil overexpression and asthma severity were made in 1990 by Bousquet et al. 29 Multiple studies have since confirmed that blood, tissue, or sputum eosinophil counts can be used to characterize patients with severe asthma and eosinophilic inflammation. [30] [31] [32] [33] [34] [35] [36] [37] Through the drug development process for mepolizumab, investigators identified blood eosinophils, rather than sputum eosinophils, as the treatment target for mepolizumab, providing an accessible and multipurpose biomarker for severe eosinophilic asthma. 18, 19, 38, 39 This review will examine how evidence generated during the mepolizumab clinical development program showed that the blood eosinophil count can serve as a pharmacodynamic and predictive biomarker in patients with severe eosinophilic asthma.
PHARMACODYNAMIC BIOMARKERS FOR MEPOLIZUMAB TREATMENT RESPONSE
Mepolizumab binds with high specificity and affinity to human IL-5, 40 the key T2 cytokine responsible for regulation of blood and tissue eosinophils. 41 Mepolizumab prevents IL-5 from binding to the a chain of the IL-5 receptor complex expressed on the eosinophil cell surface and thus inhibits IL-5 signaling, blocking eosinophil survival and proliferation. Although the exact mechanism of action of IL-5 inhibitors is not fully elucidated, the desired physiologic goal is to neutralize the effect of activated eosinophils in blood and tissues, such as the lung.
During the development of mepolizumab, the pharmacodynamic response was assessed in blood, sputum, and tissue eosinophils. [18] [19] [20] 42, 43 Early studies showed that mepolizumab produced modest reductions in airway tissue and bone marrow eosinophil counts, suggesting limited pharmacodynamic effects in these compartments. 9 Haldar et al 43 then showed that treatment with 750 mg of intravenous mepolizumab in patients with severe asthma and sputum eosinophil counts of greater than 3% at least once in the previous 2 years reduced blood and sputum eosinophil counts during treatment, although sputum eosinophilia was present in 36% of exacerbations despite mepolizumab therapy.
After this, the Dose Ranging Efficacy and safety With Mepolizumab in Severe Asthma (DREAM) study (NCT01000506) was conducted, which was a phase 2b/3 clinical trial of mepolizumab in patients with severe asthma and eosinophilic inflammation and included assessments of the pharmacodynamic response of mepolizumab. 19 The inclusion criteria for the DREAM study are shown in Fig 1. Patients in the DREAM study received either placebo or 75, 250, or 750 mg of intravenous mepolizumab, representing a 10-fold dose range. At the 750-mg intravenous dose, there were comparable reductions of 88% in blood and sputum eosinophil counts; however, for the 250-mg intravenous dose, the reduction in blood eosinophil counts was 86% compared with 65% for sputum, and for the 75-mg intravenous dose, the reduction in blood eosinophil counts was 78% compared with 32% for sputum (Fig 2) . 19 All doses of mepolizumab had similar beneficial effects on the primary outcome measure, the rate of clinical significant asthma exacerbations.
A second study 42 assessing a range of subcutaneous doses (12.5, 125, or 250 mg administered subcutaneously vs 75 mg administered intravenously) showed that this reduction in blood eosinophil count occurred 2 days after the first dose of mepolizumab, was dose dependent, and was not affected by administration route (intravenous vs subcutaneous) after adjusting for bioavailability.
Overall, results from the DREAM study and Pouliquen et al 42 suggest that blood eosinophil but not sputum or tissue eosinophil counts are the key pharmacodynamic biomarker response to mepolizumab treatment in patients with severe eosinophilic asthma. This is reflected by the reduction in exacerbation rates with mepolizumab versus placebo in these patients. Since then, studies of mepolizumab in patients with hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic esophagitis all show a consistent pharmacodynamic effect of mepolizumab on eosinophils that can be measured easily and reproducibly by using blood eosinophil counts. 18, 19, 42, [44] [45] [46] [47] In addition to blood eosinophil counts, other potential pharmacodynamic biomarkers, such as fraction of exhaled nitric oxide (FENO), were assessed during the development of mepolizumab. 19, 43 Nitric oxide is released by several pulmonary cells, including epithelial cells, eosinophils, and macrophages, and nitric oxide levels have been shown to be increased in patients with conditions associated with inflammation, such as asthma and viral infections. In the DREAM study across the 10-fold dose range of 75 to 750 mg administered intravenously, there was no pharmacodynamic response with FENO (Fig 2) . 19 This lack of response to FENO was also shown in the earlier mepolizumab study by Haldar et al. 43 This suggests that FENO is not responsive to modulation through the IL-5 pathway and is potentially more relevant to different aspects of the T2 inflammatory response (eg, IL-13).
Because the clinical efficacy of mepolizumab was similar across all doses of mepolizumab (75, 250 , and 750 mg), it was decided to progress the lowest dose (75 mg administered intravenously) of mepolizumab in further phase 3 studies. The decision to take the lowest dose forward was supported by data that suggested that a dose of 75 mg administered intravenously (and the comparable exposure dose of 100 mg administered subcutaneously) was the minimum dose required to significantly reduce eosinophil counts. 42 In the subsequent clinical trials that have used the 100-mg subcutaneous dose (which has comparable systemic exposure to 75 mg administered intravenously), mepolizumab reduced exacerbation rates similar to the rate reduction achieved with higher doses of mepolizumab. 18, 48, 49 In the SIRIUS trial (NCT01691508), mepolizumab at a dose of 100 mg administered subcutaneously was shown to reduce the requirement for daily OCS while significantly improving asthma control, lung function, and quality of life. 18, 20 In the MUSCA trial (NCT02281318) patients treated with mepolizumab reported an improvement in Asthma Control Questionnaire scores. This also corresponded to an observed improvement in patients' quality of life, as measured by using the St George Respiratory Questionnaire. 48 Results from the Steroid Reduction with Mepolizumab Study (SIRIUS) trial were comparable with the OCS-sparing effects seen during a trial with mepolizumab at 750 mg administered intravenously, 48 providing further indirect clinical evidence that a DREAM study population:
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• higher dose of mepolizumab is not required to achieve maximum efficacy benefits. Taken together, pharmacodynamic responses to mepolizumab in the blood and sputum informed the therapeutic dose across a 10-fold dose range. Blood pharmacodynamic responses showed that a dose of 100 mg of mepolizumab administered subcutaneously provides the desired pharmacology to neutralize serum IL-5 levels and reduce blood eosinophil counts to approximately 40 cells/mL, which corresponds to a low normalized blood eosinophil count. [18] [19] [20] 48 Interestingly, dose-dependent pharmacodynamic responses in blood suggest that complete depletion of eosinophil counts in the blood compartment is not necessary to achieve maximal clinical efficacy. Correspondingly, in clinical trials blood eosinophil counts are consistently reduced to approximately 40 cells/mL rather than fully depleted. [18] [19] [20] Furthermore, this reduction occurs with mepolizumab doses ranging from 75 mg administered intravenously/100 mg administered subcutaneously to 750 mg administered intravenously, suggesting that increasing the mepolizumab dose would not further reduce blood eosinophil counts.
Outside of the mepolizumab clinical trial program, recent studies have shown that benralizumab can deplete blood eosinophils to a higher degree than mepolizumab or reslizumab, 50, 51 and this differentiated mechanism of action has led some investigators to suggest that benralizumab might prove to be more efficacious than mepolizumab or reslizumab. 52 Although no head-to-head data exist, in the phase 3 SIROCCO (NCT01928771) and CALIMA (NCT01914757) trials, benralizumab reduced the annual rate of exacerbations by 28% to 51% versus placebo in patients with blood eosinophil counts of 300 cells/mL or greater at baseline, 14, 15 which does not exceed the exacerbation reductions achieved in similar studies of mepolizumab and reslizumab. 17, 18, 20 Similarly, in a post hoc analysis of SIROCCO and CALIMA trials, benralizumab reduced the annual rate of exacerbations by 36% to 42% in patients with blood eosinophil counts of 150 cells/mL or greater at baseline by using an 8-week dosing regimen. 53 In addition, effects on asthma control and quality of life appeared to be less prominent than in mepolizumab studies when assessed according to blood eosinophil counts at baseline. 14, 15, 18, 20 This further supports the observation from the DREAM study that a maximal degree of eosinophil depletion in the blood is not necessary to achieve maximal clinical efficacy. In fact, recent animal data suggest that the eosinophil population might contain a specific subtype of eosinophils that contribute to homeostatic immune processes, and therefore targeting complete deletion of eosinophils might not be desirable. 54 
PREDICTIVE BIOMARKERS FOR MEPOLIZUMAB TREATMENT RESPONSE
Identifying a predictive biomarker for response to treatment was one of the main aims of the mepolizumab clinical development program. As such, initial modeling analyses of the DREAM study were carried out to identify characteristics that could predict treatment response. In the exploration for biomarkers predictive of treatment response, the frequency and severity of exacerbations were considered the principal clinically relevant end points. Although other highly relevant measures, such as lung function, are known to be improved during mepolizumab treatment, 18, 20, 48 these end points were secondary to the frequency of exacerbations. Analyses investigated various clinical characteristics as individual covariates in the DREAM study (ie, sex, age, weight, geographic region, baseline forced expiratory volume, airway reversibility at screening, number of exacerbations in the previous year, baseline blood eosinophil count, baseline use of maintenance OCSs, and IgE count) to distinguish which variables were predictive of more frequent exacerbations and differential efficacy of mepolizumab (Fig 1) . 19 The model identified blood eosinophil counts as the strongest predictor of reduction in exacerbation rates with mepolizumab compared with placebo. 19 Consequently, in a post hoc analysis of the DREAM study, it was found that a blood eosinophil count threshold of 150 cells/mL or greater combined with other clinical characteristics, such as exacerbation rate, could predict response to treatment with mepolizumab. Blood eosinophil counts at baseline were also a better predictor of response than sputum eosinophil counts. Furthermore, treatment-related effects on blood eosinophil counts related more closely to clinical benefits than effects on sputum eosinophil counts, leading us to believe that suppression of blood eosinophil counts is crucial to efficacy. 19 The initial modeling analysis from the DREAM study was repeated for the phase 3 Mepolizumab Adjunctive Therapy in Subjects with Severe Uncontrolled Refractory Asthma (MENSA) study (NCT01691521) 18 and also showed that there is a direct relationship between baseline blood eosinophil counts and reduction in exacerbation rates (Fig 3) . 55 This was confirmed in a clinical evaluation of the alternative anti-IL-5 therapies reslizumab 56 and benralizumab 14 in which patients with blood eosinophil counts of greater than 400 or 300 cells/mL, respectively, derived greater clinical benefit from the therapy compared with those with eosinophil counts of less than the threshold. 14, 56 At 150 cells/mL, the predicted reduction in exacerbation rate was estimated to be 30% and 39% in the DREAM and MENSA studies, respectively, both representing clinically meaningful reductions in exacerbation rates. 55 Thus although both studies showed a reduction in exacerbation rates of approximately 50% in the overall population, 18, 19 the model predicted a clinically important 30% or greater reduction in exacerbation rates in patients with baseline blood eosinophil counts of 150 cells/mL. This was similar to a subanalysis of 2 benralizumab studies focusing on patients with eosinophil counts of greater than 150 cells/mL, in which the therapy reduced exacerbation rates by 32% and 42%. 53 Although 150 cells/mL is the minimal cutoff to observe meaningful clinical benefit, the majority of the patients in the mepolizumab program have blood eosinophil counts of 300 cells/mL or greater. However, using a blood eosinophil count threshold of 300 cells/mL to identify patients for treatment might exclude 25% of patients with severe asthma with an eosinophil count in the range of 150 to 300 cells/mL who might benefit from treatment. A meta-analysis of patients from the DREAM and MENSA studies showed that patients with blood eosinophil counts of 150 or greater to less than 300 cells/mL at baseline achieved a 33% reduction in annual clinically significant exacerbations (rate ratio [RR], 0.67; 95% CI, 0.45-1.01). 55 Because the DREAM and MENSA studies had different inclusion criteria to identify patients with severe eosinophilic asthma (Table I) , additional analyses have been carried out to corroborate the clinical benefit of mepolizumab based on blood eosinophil counts. The DREAM study used 4 criteria to identify patients with eosinophilic inflammation, as shown in Fig 1. In contrast, the MENSA study defined eosinophilic inflammation as a blood eosinophil count of 150 cells/mL or greater at screening or 300 cells/mL or greater at some time during the previous year. A post hoc analysis of the primary end point for the DREAM study was conducted by using the blood eosinophil criteria used in the MENSA study to assess the effect of these different criteria. This analysis showed that patients treated with mepolizumab who met the blood eosinophil criteria had a 50% reduction in exacerbation rates over those receiving placebo compared with a 10% reduction in patients who did not meet either blood eosinophil criteria (Table I) . 55 Further analysis of the combined DREAM and MENSA study population showed that clinically relevant reductions in exacerbations were also achieved in patients who met either of the 2 blood eosinophil criteria (Table II) . Taken together, these data show that either criterion (historical or baseline) is predictive of response. 55 These results support the utility of the evaluated blood eosinophil counts as a biomarker to identify a patient likely to benefit from treatment with mepolizumab.
Although sputum eosinophil measurements have been correlated with airway eosinophilia, further analysis of the DREAM study showed that sputum eosinophil counts did not predict response mepolizumab treatment. 38 In the 94 patients from the sputum substudy of the overall DREAM study, exacerbation rates were reduced by approximately 70% in both patients with a sputum eosinophil count of 3% or greater (RR, 0.31; 95% CI, 0.17-0.59) and those with a count of less than 3% (RR, 0.34; 95% CI, 0.13-0.93). 36 In the whole study, when analyzed based on blood eosinophil counts, exacerbation rate reductions were 72% for counts of 150 cells/mL or greater (RR, 0.28; 95% CI, 0.14-0.54) compared with 30% for counts of less than 150 cells/mL (RR, 0.70; 95% CI, 0.21-2.34). 38 This lack of differential response with sputum eosinophil counts has been debated because it seems more intuitive that sputum eosinophil counts would be more predictive of treatment response than blood eosinophil counts. Although the DREAM sputum substudy was based on 94 adult patients, a recent study in patients with severe asthma suggested that exacerbation frequency is associated with increasing sputum eosinophil counts. 57 An extension of the knowledge that blood eosinophil counts of greater than 150 cells/mL are predictive of response to mepolizumab is that a blood eosinophil count of less than 150 cells/mL might be considered predictive of nonresponse (Gunsoy et al, personal communication). FENO has also been evaluated as a predictive biomarker for treatment with mepolizumab. However, additional analysis of the DREAM study has also shown that a FENO value of 50 ppb or greater does not act as a predictive biomarker for reductions in exacerbation rates with mepolizumab (Fig 4) . 19 In the analysis of the DREAM data, no other early response markers were identified that provided additional predictive value compared with blood eosinophil counts (Gunsoy et al, personal communication).
DIAGNOSTIC BIOMARKERS FOR AIRWAY EOSINOPHILIA
In patients managed according to GINA Step 4 therapeutic interventions 1 who continue to have poorly controlled severe asthma, a detailed investigation is required. This might include evaluation of IgE levels and eosinophil counts to identify whether a specific asthma phenotype is present and to determine the optimal GINA Step 5 course of therapy. 1 Although sputum eosinophil counts of 2% or greater to 3% have traditionally been correlated with airway eosinophilia, 19, 58, 59 better biomarkers might exist. The utility of blood eosinophil counts as a diagnostic biomarker for airway eosinophilia has been evaluated by assessing the relationship between blood and sputum eosinophil counts. 18, 19, 21, 23 In the DREAM study, using 76 paired samples at screening of blood and sputum eosinophil counts from the sputum substudy, a screening blood eosinophil count of 150 cells/mL or greater was associated with sputum eosinophilia (> _2%) in 9 of 10 patients. 39 A blood eosinophil count of 150 cells/mL or greater also correctly predicted sputum eosinophilia with a sensitivity of 85% (95% CI, 73% to 93%) and specificity of 75% (95% CI, 48% to 93%; Fig 5) . 39 At this threshold, only 4 (5%) patients did not have sputum counts of 2% or greater. If the blood threshold was increased to 300 cells/mL, this excluded only 1 patient who did not have a sputum count of 2% or greater but conversely excluded 25 patients who did have a sputum count of 2% or greater. 39 This indicates that not only does the blood eosinophil count act as a pharmacodynamic and predictive biomarker for mepolizumab treatment but that it also acts as a diagnostic biomarker for severe eosinophilic asthma in patients with a history of 2 or more exacerbations in the past 12 months despite the use of high-dose ICSs plus additional controllers.
Independent studies corroborate that a blood eosinophil count threshold of approximately 150 cells/mL is associated with sputum eosinophilia, 60, 61 whereas other studies report that a threshold of 150 cells/mL is not associated with sputum eosinophilia and generally place the threshold around 300 cells/mL. 62, 63 It is important to recognize that the threshold is very much dependent on the populations studied. Recent analyses have demonstrated that in patients with severe asthma, blood and sputum eosinophil counts can be increased by reducing doses of ICSs and OCSs and vice versa. 64, 65 This has been corroborated by a post hoc analysis of the SIRIUS trial, which showed that the OCS dose is inversely correlated with blood eosinophil counts. 66 For the studies that showed sputum eosinophilia to be associated with a blood eosinophil count of approximately 300 cells/mL, patients were not necessarily receiving high-dose ICSs, and the use of OCSs was minimal. 62, 63 Conversely, for the studies that showed a robust association between airway eosinophilia and a blood eosinophil count threshold of approximately 150 cells/mL, nearly all patients were receiving high-dose ICSs, and about a quarter of patients were also receiving OCS doses typical for patients with severe asthma. 60, 67 Overall, the evidence shows that a blood eosinophil threshold of 150 cells/mL identifies patients with severe eosinophilic asthma receiving guideline-directed treatment.
Because blood eosinophil counts can vary on a daily basis, it is important to understand the effect of this variability. For this reason, the reproducibility of blood eosinophil counts as a diagnostic biomarker was assessed in post hoc analyses of the DREAM and MENSA studies for patients receiving placebo. 38, 68 In the DREAM study, of the 115 patients with a blood eosinophil count of 150 cells/mL or greater at screening, 98 (85%) remained at greater than this threshold in their postscreening average, with a mean postscreening average of 168 cells/mL (95% CI, 149-189 cells/mL) across the year. 38 Similar results were obtained from the 167 patients from the MENSA study with a blood eosinophil count of 150 cells/mL or greater at screening, with 86% having a count of 150 cells/mL or greater over the following 8 months. 68 In both analyses multiple measurements only marginally increased sensitivity, meaning that a single measurement was adequate to identify patients with severe eosinophilic asthma. Overall, this suggests that a single blood eosinophil count of 150 cells/mL or greater in concert with other clinical markers of severe disease can be used effectively as a diagnostic biomarker for airway eosinophilia in a population with severe asthma that continues to exacerbate despite the use of high-dose ICSs plus additional controllers.
DISCUSSION AND CONCLUSIONS
Validation and qualification of biomarkers is crucial to their successful use and should include confirmation of sensitivity, specificity, and reproducibility. 69 Through the mepolizumab clinical development program, the blood eosinophil count has been assessed for use as a pharmacodynamic and predictive biomarker. First, it was established that blood eosinophil counts, rather than sputum eosinophil counts, are the more useful pharmacodynamic biomarker for mepolizumab. 19, 42 Second, and crucially for clinical decision making, blood eosinophil counts can be used to identify a patient likely to benefit from mepolizumab treatment in terms of reduction in exacerbation rates, as demonstrated by the direct relationship between baseline blood eosinophil counts and the predicted exacerbation rate shown in analyses of the DREAM and MENSA studies. 18, 19, 55 Although several diverse approaches were taken during the development of mepolizumab to examine whether novel protein or genetic markers were an indicator of eosinophilia, no marker emerged that was more predictive of treatment effect than the blood eosinophil count obtained from a simple complete blood count. Importantly for its routine clinical use, measurement of blood eosinophil counts is practical and minimally invasive in comparison to collection of sputum samples. These qualities mean that information to support clinical decision making can be easily accessible to health care providers during routine care. A blood examination is also relatively inexpensive, and the results can be available in a short period of time after collection. Importantly, the data suggest that a single measurement is sufficient to identify a blood eosinophil count of 150 cells/mL or greater in approximately 85% of patients. 38, 68 This compares favorably with the use of hemoglobin A 1C in patients with diabetes, where a single measurement can be used to assess average blood glucose control over 3 months. 70, 71 In addition to biomarker evaluation, the DREAM and MENSA studies refined the target population for mepolizumab treatment to patients with severe asthma with frequent exacerbations despite high-dose ICSs plus additional controllers or dependency on OCSs and quantified the thresholds required to predict treatment response. Taking into account that patients treated with high doses J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 6 of ICSs (and OCSs) might have reduced blood eosinophil counts, from the model developed, the threshold of 150 cells/mL provides a reliable means to identify the patient population with severe asthma that is likely to benefit from mepolizumab treatment. 55 Additionally, historical blood eosinophil counts (> _300 cells/mL) allow flexibility to start a patient with severe asthma immediately on treatment if deemed appropriate by the health care provider. 55 Of course, as with all biomarker use, deriving a credible health effect with the use of blood eosinophil counts requires the use of sound clinical judgement to incorporate biomarker measurement information into a clinically relevant patient management strategy. 72 This is particularly important in clinical practice, where a range of blood eosinophil counts can be predictive of exacerbation risk given the heterogeneous nature of asthma populations. 60, [73] [74] [75] As such, individual symptoms, disease patterns, and treatment goals must be considered as part of the treatment decision-making process, and exacerbation history is key in this regard.
With the introduction of further predictive biomarkers for use in patients with severe asthma, as well as the growing number of targeted biological therapies available, decisions regarding biomarker use in a particular patient are complex. The decision to treat a patient with severe eosinophilic asthma who is likely to benefit from an anti-IL-5 therapy might not be straightforward because the underlying mechanisms responsible for poor asthma control and airway eosinophilia might be due to heterogeneous T2 inflammatory pathways. 41 It is also documented that some patients with severe asthma have both activated T2 and T1 inflammatory pathways. 76 It is possible that future research can identify a composite of different biomarkers rather than a single biomarker to help target biological therapies to individual pathology. Currently, there are no head-to-head studies comparing the efficacy of anti-IgE and anti-IL-5 biologic therapies, but such studies might be difficult because of sample size estimates. Therefore use of clinical end points and available biomarkers should help select the appropriate patients for these treatment options.
Several aspects of treatment with mepolizumab require further investigation. Mepolizumab is indicated currently in adults and adolescents, but further research is needed to understand its efficacy, pharmacokinetics, and pharmacodynamics in children. As more biological therapies become available, the effect of switching from one therapy to another should be evaluated. Finally, a deeper understanding of the pharmacoeconomics of the use of biologics in the management of severe eosinophilic asthma is warranted.
In conclusion, stratification of patients with severe asthma to guide treatment decisions is complex, and reliable and sensitive biomarkers are a valuable tool for physicians in this regard. Data from the mepolizumab clinical trial program support the use of baseline blood eosinophil counts as a sensitive and practical predictive biomarker for mepolizumab treatment effect in patients with severe eosinophilic asthma with frequent exacerbations, despite optimal standard of care or are dependent on maintenance OCS therapy. In combination with sound clinical judgement, use at a baseline blood eosinophil count threshold of 150 cells/mL or greater and/or a historical blood eosinophil count threshold of 300 cells/mL or greater will allow selection of patients who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment.
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